Leerink reiterates Outperform on MannKind stock, sees overreaction By Investing.com

Leerink Partners reiterated an Outperform rating and $7.00 price target on MannKind, arguing the stock is significantly undervalued even under aggressive bear-case assumptions for Tyvaso DPI royalty erosion. The firm sees Furoscix as a potential growth inflection point ahead of the autoinjector PDUFA date on July 26, 2026, with roughly 70% COGS reduction supporting margins. MannKind shares are already down about 54% since the TreSMI news and 60% from the 52-week high, suggesting the stock may be pricing in overly negative outcomes.

Analysis

The market is treating the TreSMI risk as a binary kill-shot to MNKD’s royalty stream, but the more important issue is duration mismatch: the equity is discounting an accelerated erosion curve while the cash flows are likely to decay more gradually, leaving room for multiple expansion if launch adoption is slower than feared. That creates an asymmetric setup where even a modestly less severe competitive takeout can re-rate the stock materially because expectations are already at trough-like levels.

The bigger second-order beneficiary is UTHR, but not purely from product share. A successful alternative delivery system could reinforce category leadership and widen the moat around the broader Tyvaso franchise, while pressuring smaller inhaled-therapy peers to spend more on differentiation, payer access, and device usability. In other words, the winner is not just the molecule; it is the integrated drug-device platform, which could raise the bar for any future respiratory royalty model.

MNKD’s near-term catalyst stack is uneven: the downside is immediate on sentiment, but the upside is staggered over months as launch data, royalty durability, and FUROSCIX traction become visible. The more actionable point is that the market may be underweighting the gross-margin step-change from the autoinjector path; if that inflects, it can dominate the Tyvaso headline risk because mix improvement tends to compound faster than investors model it.

Contrarian takeaway: this is less a ‘royalty destroyed’ story than a ‘multiple reset before evidence’ story. If the soft mist launch is initially constrained by reimbursement friction, prescriber inertia, or device-switching complexity, MNKD should stabilize well before fundamental consensus catches up, while UTHR remains the cleaner quality compounder. The risk to the bearish case is that investors are extrapolating perfect substitution too early, which is usually the wrong way to price specialty pharma transitions.

Key Decisions for Investors

• Buy MNKD on weakness over the next 2-6 weeks with a tight thesis stop: downside appears increasingly capped if TreSMI adoption is gradual, while any evidence of royalty stability could drive a 20-30% rebound from depressed levels.
• Structure MNKD call spreads into the July 26, 2026 FUROSCIX autoinjector decision window; the payoff is convex if the market starts capitalizing the gross-margin step-up before approval.
• Long UTHR vs short MNKD as a pair for 3-9 months: UTHR captures the cleaner franchise-quality rerating, while MNKD carries the asymmetry of royalty uncertainty and product-execution risk.
• Avoid chasing MNKD put premium after the selloff; implied fear likely overstates the pace of erosion, so short-dated downside protection is expensive relative to the remaining information gap.